Statute Details
- Title: Medicines (Clinical Trials) Regulations 2016
- Act Code: MA1975-S335-2016
- Type: Subsidiary legislation (SL)
- Enacting Act: Medicines Act (Cap. 176)
- Enacting power: Section 18 of the Medicines Act
- Commencement: 1 November 2016
- Status: Current version (as at 27 Mar 2026)
- Parts: Part 1 (General), Part 2 (Clinical Trials of Medicinal Products), Part 3 (Miscellaneous), Part 4 (Application to Pending Clinical Trials)
- Key regulatory themes: Clinical trial certification, sponsor/investigator duties, consent and information, safety vigilance and reporting, labelling requirements, offences and enforcement
- Notable amendments (timeline shown): S 1047/2021; S 440/2023; S 812/2023
What Is This Legislation About?
The Medicines (Clinical Trials) Regulations 2016 (“MCTR”) set out the regulatory framework in Singapore for conducting clinical trials of medicinal products. In practical terms, the Regulations require clinical trials to be authorised through a clinical trial certificate and impose detailed obligations on the sponsor and investigator to protect trial subjects, ensure good clinical practice, and maintain robust safety and reporting systems.
Although clinical trials are often described as “research”, the MCTR treats them as a regulated activity with direct public health implications. The Regulations therefore focus on (i) governance and authorisation (certificates and conditions), (ii) ethical and legal safeguards for subjects (consent, information, and protections against coercion), (iii) operational conduct (good clinical practice and adherence to the certificate), and (iv) pharmacovigilance (reporting serious adverse events and unexpected serious adverse drug reactions). They also address practical compliance matters such as labelling of investigational medicinal products.
Scope-wise, the Regulations apply to “clinical trials of medicinal products” that are not observational trials (as indicated by the scope provision in the extract). They sit alongside Singapore’s broader biomedical research and healthcare regulatory regimes, including the Human Biomedical Research Act 2015 (HBRA) and the Healthcare Services Act 2020 (HCSA), particularly where institutional review boards (IRBs) and licensed healthcare services are involved.
What Are the Key Provisions?
1. Definitions and foundational concepts (Part 1)
The Regulations begin with definitions that anchor the regulatory obligations. Key terms include adverse event, adverse drug reaction, investigational medicinal product, auxiliary medicinal product, investigator’s brochure, and institutional review board. These definitions matter because they determine when reporting duties are triggered and what documentation and labelling requirements apply.
Notably, the Regulations define a clinical trial in an emergency situation—a category designed to address the reality that some patients cannot consent and it may not be feasible to obtain consents from legal representatives within the relevant time window. This definition is important because it supports a tailored consent regime (discussed below) while still requiring safeguards.
2. Scope and applicability (regulation 3)
The scope provision indicates that the Regulations apply to clinical trials of medicinal products that are not observational trials. For practitioners, this is a threshold question: if a study is truly observational (and not interventional with an investigational medicinal product), the MCTR may not apply in the same way. Conversely, if the study involves testing or using a medicinal product (including a placebo) as part of a trial, the MCTR’s certificate and compliance obligations are likely engaged.
3. Clinical trial certification and regulatory submissions (Division 2 of Part 2)
A central compliance requirement is the requirement for clinical trial certificates (regulation 7). The certificate concept functions as the regulatory “permission slip” to conduct the trial. The Regulations also set out the application process (regulation 8) and the conditions attached to certificates (regulation 9). Conditions can be expected to cover matters such as protocol requirements, subject protections, safety monitoring, and reporting timelines.
Regulation 10 addresses amendments and substantial amendments to clinical trials. This is critical in practice because protocols evolve as trials progress. Sponsors and investigators must manage change control carefully: not every modification may require the same level of regulatory action, but “substantial amendments” will typically require prior approval or notification depending on the regulatory scheme.
Regulations 11 and 12 impose notification duties—including notification of serious breaches and urgent safety measures, and notification of the status of the clinical trial. These provisions ensure that the regulator is informed not only of adverse outcomes but also of compliance failures and immediate risk mitigation steps.
4. Conduct of trials: good clinical practice and adherence to the certificate (Divisions 1 and 3)
The Regulations require that clinical trials be conducted in accordance with good clinical practice (regulation 13) and in accordance with the clinical trial certificate (regulation 14). The Regulations also include a provision on the place of clinical trial (regulation 15), which is relevant where trials must be conducted at approved or suitable facilities (and where healthcare service licensing concepts may be relevant).
The First Schedule sets out Principles of good clinical practice. While the extract does not reproduce the schedule text, the schedule is designed to translate international best practices into Singapore’s legal requirements. For lawyers advising sponsors, this schedule is often the benchmark for assessing whether trial conduct meets regulatory expectations.
5. Consent, information, and protections against coercion (Subdivision 2 of Division 3)
A major ethical and legal component is the consent regime. Regulations 16 to 20 address consent of subjects, consent in emergency situations, general requirements as to consent, the duty to provide full explanation and information, and coercion.
In general, subjects must be given adequate information and must consent voluntarily. The duty to give a full explanation and information (regulation 19) is particularly important for informed consent quality—lawyers should expect that consent forms and consent processes must be robust, understandable, and consistent with the protocol and certificate.
Regulation 20 prohibits coercion. This is a compliance risk area in clinical settings where patients may feel pressure due to their relationship with clinicians or institutional authority. Sponsors and investigators must ensure that recruitment and consent processes are designed to avoid undue influence.
For emergency trials, regulation 17 provides a tailored consent pathway consistent with the definition in regulation 2. The legal significance is that the Regulations recognise time-critical medical circumstances while still requiring that consent-related safeguards be implemented as soon as feasible.
6. Safety duties: urgent safety measures, suspension or termination (Subdivision 3 of Division 3)
The Regulations impose ongoing safety obligations. Regulation 21 requires urgent safety measures where necessary. Regulation 22 provides for suspension or termination of a clinical trial in appropriate circumstances. These provisions are designed to ensure that when risks emerge, trial conduct can be rapidly adjusted or halted to protect subjects.
7. Records and information: record of clinical trials (Subdivision 4 of Division 3)
Regulation 23 requires a record of clinical trials. Record-keeping is not merely administrative; it is essential for demonstrating compliance, enabling audits/inspections, and supporting safety reporting and regulatory review.
8. Vigilance and pharmacovigilance reporting (Division 4 of Part 2)
The Regulations include explicit reporting duties for safety signals. Regulation 24 requires notifications of serious adverse events, and regulation 25 requires notifications of unexpected serious adverse drug reactions. These duties reflect the distinction between any serious adverse event (which may or may not be causally related) and a serious adverse drug reaction that is unexpected and related to the investigational product.
For practitioners, the key is to ensure that the sponsor’s safety management system can identify, classify, and report events within the required timelines and in the required format. Misclassification (e.g., treating an unexpected serious adverse drug reaction as a non-reportable event) can create regulatory exposure.
9. Labelling requirements (Division 5 of Part 2)
Regulation 26 requires labelling of the investigational medicinal product and auxiliary medicinal product. The Second Schedule sets out Labelling requirements. Labelling compliance is a practical but high-impact area: incorrect labelling can lead to dosing errors, mix-ups, and compromised subject safety, and it can also undermine trial integrity and traceability.
10. Miscellaneous: information powers and offences (Part 3)
Regulation 27 provides the power to obtain information, supporting regulatory oversight. Regulation 28 sets out offences. While the extract does not reproduce the offence provisions, the existence of an offences section signals that non-compliance with certificate requirements, consent duties, safety reporting, labelling, and record-keeping can attract criminal or regulatory penalties.
11. Pending trials (Part 4)
Regulation 29 addresses revocation and pending clinical trials. This transitional provision is important for sponsors who had trials ongoing at the time of amendments or when the Regulations were first introduced. It helps determine how the new rules apply to trials already in progress and whether certificates or approvals need to be updated.
How Is This Legislation Structured?
The MCTR is organised into four parts. Part 1 contains the citation/commencement and definitions, establishing key terms used throughout the Regulations. Part 2 is the core regulatory framework and is divided into five Divisions: (i) general sponsor/investigator and documentation requirements; (ii) regulatory submissions and clinical trial certificates; (iii) general duties covering good clinical practice, consent, safety, and records; (iv) vigilance reporting; and (v) labelling. Part 3 contains miscellaneous provisions including information powers and offences. Part 4 addresses how the Regulations apply to pending clinical trials, including revocation and transitional treatment. Two schedules supplement the main text: the First Schedule (principles of good clinical practice) and the Second Schedule (labelling requirements).
Who Does This Legislation Apply To?
The Regulations apply to parties involved in clinical trials of medicinal products in Singapore, particularly sponsors and investigators. The sponsor/investigator roles are central because the Regulations allocate responsibilities across trial governance (certificates and conditions), subject protections (consent and information), safety management (urgent measures, suspension/termination, vigilance reporting), and operational compliance (records and labelling).
In addition, the Regulations’ definitions and cross-references indicate interaction with other Singapore regulatory regimes. For example, the definition of institutional review board links to the Human Biomedical Research Act 2015, and definitions for “approved permanent premises” and “licensable healthcare service” link to the Healthcare Services Act 2020. Practically, this means that trial sites and ethics review processes must align with the relevant statutory frameworks.
Why Is This Legislation Important?
The MCTR is important because it operationalises the Medicines Act’s policy goal: ensuring that clinical trials are conducted safely, ethically, and with adequate regulatory oversight. For lawyers, the Regulations provide the legal standards against which trial conduct can be assessed—particularly around consent quality, safety reporting, and adherence to certificate conditions.
From an enforcement perspective, the presence of offences and regulatory information powers means that non-compliance can lead to significant consequences. Sponsors should therefore treat the MCTR not as a “best practice” guide but as a binding compliance regime. This is especially true for vigilance reporting (serious adverse events and unexpected serious adverse drug reactions), where delays or failures can create both subject harm risk and regulatory exposure.
Practically, the Regulations also influence how trial documentation is drafted and maintained: protocols, consent forms, investigator brochures, labelling artwork, and safety management plans must be consistent with the certificate and with the Regulations’ schedules and definitions. For ongoing trials, Part 4’s transitional provisions and regulation 10’s change-control requirements mean that legal review should be built into protocol amendment workflows.
Related Legislation
- Medicines Act (Cap. 176)
- Human Biomedical Research Act 2015
- Healthcare Services Act 2020
- Medical Registration Act 1997
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Medicines (Clinical Trials) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.